These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 5292810)

  • 21. Levodopa and induced-pain response. A study of patients with Parkinsonian and pain syndromes.
    Battista AF; Wolff BB
    Arch Intern Med; 1973 Jul; 132(1):70-4. PubMed ID: 4716428
    [No Abstract]   [Full Text] [Related]  

  • 22. [Problems in methods of evaluation of parkinsonian symptoms in a therapeutic trial].
    De Renzi E
    Sist Nerv; 1970; 22(2):115-8. PubMed ID: 5504549
    [No Abstract]   [Full Text] [Related]  

  • 23. [L-Dopa-Propranolol association and parkinsonian trembling].
    Kissel P; Tridon P; Masingue M; Andre JM
    Nouv Presse Med; 1972 Jul; 1(29):1943. PubMed ID: 5053603
    [No Abstract]   [Full Text] [Related]  

  • 24. [Our experience in the treatment of the parkinsonian syndrome with L-dopa. I. Evaluation of the clinical results].
    Bergamini L; Bonzanino O; Brignolio F; Fabiani A; Fariello R; Mombelli AM; Mutani R; Pisani W; Postir A; Riccio A; Sabbatini F; Sandigliano G; Schiffer D
    Riv Patol Nerv Ment; 1969 Oct; 90(5):329-49. PubMed ID: 5406104
    [No Abstract]   [Full Text] [Related]  

  • 25. Impaired potentiation of H-reflexes in patients with Parkinson's disease.
    Sica RE; Aguilera N; Herskovits E
    Medicina (B Aires); 1972; 32(6):588-95. PubMed ID: 4663253
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of L-dopa on speech in Parkinsonism. An EMG study of labial articulatory function.
    Leanderson R; Meyerson BA; Persson A
    J Neurol Neurosurg Psychiatry; 1971 Dec; 34(6):679-81. PubMed ID: 5158782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative effects of L-dopa on different types of movements and muscle tone in Parkinsonian patients.
    Knutsson E; Mårtensson A
    Scand J Rehabil Med; 1971; 3(3):121-30. PubMed ID: 5156174
    [No Abstract]   [Full Text] [Related]  

  • 28. [Amantadine and L-Dopa in the treatment of parkinsonian syndromes and their implications for rehabilitation].
    Raspa EG; Paciaroni E; Saccomanno G
    Minerva Med; 1971 Oct; 62(82):4031-5. PubMed ID: 5125073
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effects of L-DOPA on sleep spindles in patients with parkinsonism].
    Bricolo A; Sciarretta G; Mazza C; Turella G
    Riv Sper Freniatr Med Leg Alien Ment; 1970 Apr; 94(2):416-24. PubMed ID: 4320855
    [No Abstract]   [Full Text] [Related]  

  • 30. Functional evaluation of Parkinsonian patients treated with L-dopa.
    Mars H; Poirier F
    Can J Occup Ther; 1970; 37(4):135-40 passim. PubMed ID: 5203592
    [No Abstract]   [Full Text] [Related]  

  • 31. [Initial experiences with Levodopa in the treatment of the Parkinsonian syndrome].
    Beteta E; Gonzales-Portillo MA; Voto Bernales J
    Rev Neuropsiquiatr; 1970 Jun; 33(2):136-45. PubMed ID: 5509274
    [No Abstract]   [Full Text] [Related]  

  • 32. [Clinical experimentation of DOPA in Parkinsonian syndromes].
    Pazzagli A; Amaducci L
    Riv Neurobiol; 1966; 12(1):138-45. PubMed ID: 5959306
    [No Abstract]   [Full Text] [Related]  

  • 33. [Modern therapeutics of Parkinson's disease].
    Schott B
    Lyon Med; 1971 Nov; 226(17):539-46. PubMed ID: 5134684
    [No Abstract]   [Full Text] [Related]  

  • 34. Measurement of behavioural changes in patients on L-dopa.
    Meier MJ; Martin WE
    Lancet; 1970 Apr; 1(7650):786-7. PubMed ID: 4191295
    [No Abstract]   [Full Text] [Related]  

  • 35. Measurement of behavioural changes in patients on L-dopa.
    Fehling C
    Lancet; 1970 Apr; 1(7650):786. PubMed ID: 4191294
    [No Abstract]   [Full Text] [Related]  

  • 36. [Study of 30 parkinsonian patients treated for 6 months with L-Dopa].
    Barbizet J; Duizabo P
    Therapie; 1972; 27(1):133-40. PubMed ID: 5017549
    [No Abstract]   [Full Text] [Related]  

  • 37. [Association of L-dopa and other therapeutic methods in treatment of parkinsonian syndromes].
    Mingrino S
    Sist Nerv; 1970; 22(2):212-5. PubMed ID: 4926920
    [No Abstract]   [Full Text] [Related]  

  • 38. [Electromyographic aspects of laro-dopa therapy].
    Càmpeanu E; Mareş V; Dumitru E; Kory S
    Neurol Psihiatr Neurochir; 1973; 18(6):551-8. PubMed ID: 4790487
    [No Abstract]   [Full Text] [Related]  

  • 39. [Action of amantadine HCl alone and in combination with L-dopa on parkinsonism].
    Danielczyk W; Korten JJ
    Med Monatsschr; 1971 Oct; 25(10):472-9. PubMed ID: 5122447
    [No Abstract]   [Full Text] [Related]  

  • 40. Depressive syndromes and L-dopa treatment in Parkinsonian patients.
    Pinelli P; Pinto F; Mazza S
    Arch Psicol Neurol Psichiatr; 1971; 32(5):414-26. PubMed ID: 5145648
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.